Eli-002 7P

Gallbladder Carcinoma

Elicio TherapeuticsUNKNOWNPhase 1Active

CC

44/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 32/ 100
Competitive Position: 81/ 100

Competitive context

29 Active assets in the Gallbladder Carcinoma cohort.

Asset / Sponsor	Phase	Rating
FLUOROURACILUM Lisata Therapeutics, Inc.	Phase 2	B
OXALIPLATIN Lisata Therapeutics, Inc.	Phase 2	B
CIS-DIAMMINEDICHLOROPLATINUM II Lisata Therapeutics, Inc.	Phase 2	B
Pembrolizumab Seagen, a wholly owned subsidiary of Pfizer	Phase 2	B
Durvalumab Lisata Therapeutics, Inc.	Phase 2	B

View all 36 →

Same molecule, other indications

Eli-002 7P is also rated in:

pancreatic ductal adenocarcinomaActive

CCC

Indicative · Phase 1/2

49 / 100

colorectal cancerActive

CCC

Indicative · Phase 1/2

48 / 100

bile duct cancerActive

CC

Indicative · Phase 1

46 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.